Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer’s disease
Viral vectors
Male
JAK2-STAT3 pathway
[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology
Mice, Transgenic
Mouse models
Hippocampus
Amyloid beta-Protein Precursor
Mice
03 medical and health sciences
Apolipoproteins E
Neuroinflammation
Alzheimer Disease
Glial Fibrillary Acidic Protein
Presenilin-1
Animals
Aspartic Acid Endopeptidases
RC346-429
Extracellular Signal-Regulated MAP Kinases
Maze Learning
JAK2-STAT3 pathway
0303 health sciences
Amyloid beta-Peptides
Research
Signaling cascades
Excitatory Postsynaptic Potentials
Janus Kinase 2
Disease Models, Animal
Astrocytes
Mutation
Reactive astrocytes
Neurology. Diseases of the nervous system
Amyloid Precursor Protein Secretases
Alzheimer’s disease
DOI:
10.1186/s40478-018-0606-1
Publication Date:
2018-10-15T18:39:18Z
AUTHORS (32)
ABSTRACT
Astrocyte reactivity and neuroinflammation are hallmarks of CNS pathological conditions such as Alzheimer's disease. However, the specific role of reactive astrocytes is still debated. This controversy may stem from the fact that most strategies used to modulate astrocyte reactivity and explore its contribution to disease outcomes have only limited specificity. Moreover, reactive astrocytes are now emerging as heterogeneous cells and all types of astrocyte reactivity may not be controlled efficiently by such strategies.Here, we used cell type-specific approaches in vivo and identified the JAK2-STAT3 pathway, as necessary and sufficient for the induction and maintenance of astrocyte reactivity. Modulation of this cascade by viral gene transfer in mouse astrocytes efficiently controlled several morphological and molecular features of reactivity. Inhibition of this pathway in mouse models of Alzheimer's disease improved three key pathological hallmarks by reducing amyloid deposition, improving spatial learning and restoring synaptic deficits.In conclusion, the JAK2-STAT3 cascade operates as a master regulator of astrocyte reactivity in vivo. Its inhibition offers new therapeutic opportunities for Alzheimer's disease.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (85)
CITATIONS (168)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....